top of page
Morphing Shape

Capitalize on the Future of Medical Imaging with PreDx

With the global gene therapy market projected to reach $82.24 billion by 2032 and the increasing prevalence of osteoarthritis, the opportunity to invest in PreDx and our unique technology is both promising and timely.

We aim to capitalize on these growing markets by offering our advanced imaging technology for use in preclinical and clinical applications, transforming how both gene therapy and osteoarthritis are diagnosed and treated.

Dark-Background

By enabling real-time, non-invasive monitoring of senescent cells in osteoarthritic joints, our technology promises to revolutionize the way osteoarthritis is studied and managed. As we advance, we anticipate our bio-responsive MR contrast agents being used as companion diagnostics, paving the way for safer and more effective osteoarthritis treatments.

By reducing the number of animals required for testing and shortening trial periods, our technology promises to revolutionize the way gene therapy trials are performed. As we move into the future, we anticipate our bio-responsive MR contrast agents being used as companion diagnostics, paving the way for safer and more effective gene therapy treatments. 

 

With a firm belief in the vast potential of our technology and a commitment to advancing its application in both gene therapy and osteoarthritis, PreDx invites you to become a part of our groundbreaking journey. By investing in our cutting-edge technology, you are contributing to the transformation of the gene therapy and osteoarthritis markets, making an impact on countless lives that could benefit from these therapies. Get in touch with us today to learn more about the potential returns and how you can contribute to the evolution of healthcare. Together, we can shape the future of medicine.

bottom of page